Shanghai Nianxing Industrial Co., Ltd
China
Product Name: SM-276001
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

473930-22-2

473930-22-2 structure

473930-22-2 structure

Name: SM-276001
Chemical Name: SM-276001
CAS Number: 473930-22-2
Molecular Formula: C₁₆H₂₁N₇O
Molecular Weight: 327.38
Catalog: Signaling Pathways Immunology/Inflammation IFNAR
Create Date: 2020-06-01 14:20:05
Modify Date: 2024-01-02 16:52:59
SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer[1][2].

Name	SM-276001

Description	SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR) Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> IFNAR Research Areas >> Inflammation/Immunology
Target	TLR7; IFN[1][2]
In Vitro	SM-276001 (1 nM-10 μM) dose-dependently activates NF-κB through human TLR7[2].
In Vivo	SM-276001 demonstrates potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice[1]. Oral administration of SM-276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells[2]. SM-276001 (3 mg/kg PO biweekly) significantly inhibits tumor growth in the Renca renal cell cancer and CT26 colorectal models[2]. SM-276001 (orally; 0.1, 1 or 10 mg/kg) leads to the activation of a diverse population of spleen-resident immune effector cells in Balb/c and C57BL/6J mice. When administered at 1 mg/kg or greater, the plasma concentration of SM-276001 exceeds the MEC of 30 nM[2]. Animal Model: C57BL/6 and B6C3F1 mice bearing Renca or CT26 tumors[2] Dosage: 3 mg/kg Administration: Oral administration twice weekly for 25 days Result: Significantly reduced disease burden in mice bearing either Renca or CT26 tumors.
References	[1]. Isobe Y, et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem. 2006 Mar 23;49(6):2088-95. [2]. Koga-Yamakawa E, et al. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer. 2013 Feb 1;132(3):580-90.

Molecular Formula	C₁₆H₂₁N₇O
Molecular Weight	327.38

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.